A Swiss-based international group that runs the trials defining treatment of rare extranodal lymphomas, including primary CNS lymphoma and gastric MALT lymphoma.
Founded in 1997 and coordinated from the Oncology Institute of Southern Switzerland in Bellinzona, IELSG focuses on lymphomas arising outside lymph nodes, which no single country can study alone. IELSG32 established the MATRix regimen and consolidation strategies in primary CNS lymphoma, IELSG37 tested omission of mediastinal radiotherapy after PET-negative response in primary mediastinal B-cell lymphoma, and its gastric MALT lymphoma studies defined antibiotic and chlorambucil-rituximab therapy. It collaborates with LYSA, HOVON, the Nordic Lymphoma Group and Australian groups.
Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.
Swiss oncologist who presides over the board of the international study group that runs clinical trials in lymphomas arising outside the lymph nodes.
Shares LYSA (The Lymphoma Study Association), HOVON, Monoclonal antibodies, Diffuse large B-cell lymphoma and the tag cooperative-group.
Shares HOVON and the tag cooperative-group.
Shares FDG PET and the tag cooperative-group.
Shares IMRT / IGRT (modern external beam) and the tag cooperative-group.
Shares Nordic Lymphoma Group, Diffuse large B-cell lymphoma and the tag cooperative-group.
Shares LYSA (The Lymphoma Study Association), Monoclonal antibodies, Diffuse large B-cell lymphoma.
Shares LYSA (The Lymphoma Study Association), Diffuse large B-cell lymphoma.
Shares LYSA (The Lymphoma Study Association), Diffuse large B-cell lymphoma.